Clear Street Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $12

Benzinga · 12/30/2025 17:06
Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $12.